Stay updated on Pembrolizumab in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Glioblastoma Clinical Trial page.

Latest updates to the Pembrolizumab in Glioblastoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe record describes a completed randomized Phase I/II trial of IMA950/Poly-ICLC, with or without pembrolizumab, for relapsing glioblastoma. It also provides participant eligibility, study measures, and the trial’s location and dates.SummaryDifference52%

- Check16 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the study record remains unavailable behind a 403 error.SummaryDifference0.2%

- Check23 days agoChange DetectedA notice was added announcing NIH website updates and a transition from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision identifier was updated from v3.7.1 to v3.7.2 on the page displaying a 403 error.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 on the ClinicalTrials.gov error page; the study record remains inaccessible.SummaryDifference0.2%

- Check44 days agoChange DetectedThe page continues to show a 403 Forbidden error instead of the clinical-trial study record, with no visible content or layout changes.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Glioblastoma Clinical Trial page.